The range of psychosocial stress factors/processes (eg, chronic stress, distress states, coping, social adversity) were reviewed as they relate to immune variables in cancer along with studies of psychosocial interventions on these stress processes and immune measures in cancer populations. The review includes molecular, cellular, and clinical research specifically examining the effects of stress processes and stress-management interventions on immune variables (eg, cellular immune function, inflammation), which may or may not be changing directly in response to the cancer or its treatment. Basic psychoneuroimmunologic research on stress processes (using animal or cellular/tumor models) provides leads for investigating biobehavioral processes that may underlie the associations reported to date. The development of theoretically driven and empirically supported stress-management interventions may provide important adjuncts to clinical cancer care going forward.
Cancer May 1, 2019 defined as stress that lasts for weeks, months, or years. 10 Dysregulation of the circadian cortisol rhythm often coincides with the beginning of the harmful effects of long-term stress, 10, 18 whereas downregulation of the glucocorticoid receptor (GR) in circulating inflammatory cells is another. 19 Interindividual differences in stress perception, processing, appraisal, and coping 11 can have significant effects on the profile of the biologic stress response (Fig. 1 ). Studies in mice and rats have demonstrated differences between strains in stress hormone receptor levels and in the reactivity and peak levels of the biologic stress response, 20, 21 stress adaptation, 22 and the activation of mineralocorticoid and glucocorticoid receptors and corticosteroid-binding globulin concentrations. 20, 23 Those studies suggest that genetic and environmental factors mediate differences in stress responses and their effects on the body. 15, 23 Humans can experience psychological stress in the absence of external stressors, resulting in chronic stress and its harmful effects. It is now well established that the magnitude and duration of stress-induced elevations in stress hormones also can affect immune cell trafficking and function and, in turn, can affect health outcomes. 9, 10, 24, 25 
Effects of Chronic Stress on Immune Function: Relevance for Cancer
Immune responses are often categorized in terms of their cellular and molecular components (eg, innate, adaptive, T-helper 1 cells [Th1], Th2, Th17, etc). In addition Figure 1 . The impact of psychosocial stress and stress management on cancer-relevant immune responses is illustrated. This model summarizes the potential impact of chronic stress (chronic psychosocial adversity, depression, negative affect, anxiety, and loneliness/social isolation) on neuroendocrine processes (sympathetic nervous system [SNS] and hypothalamic-pituitaryadrenal [HPA] axis activation), which are associated with altered immune system activity (decreased immunoprotection, increased immunosuppression, and increased chronic inflammation), which, in turn, may hasten cancer progression and metastasis and decrease quality of life and survival. The model also summarizes stress management resources (social support), skills (adaptive coping and cognitive reappraisal, relaxation, mindfulness meditation, physical exercise), and pharmacologic interventions (β-adrenergic blockade and cooxygenase-2 [COX2] inhibitors), which may act to decrease chronic psychosocial adversity and/ or the modulate neuroendocrine and/or immune system processes that could contribute to positive health outcomes (decreased cancer progression and metastasis and increased quality of life and survival) (figure by FS Dhabhar).
Cancer May 1, 2019 to these mechanistic categories, it is also useful and physiologically relevant to investigate immune responses in terms of their functional end effects. Therefore, Dhabhar proposed that, while studying the immune system and its health-relevant effects, it is useful to investigate 3 functional categories of responses: immunoprotective, immunopathologic/inflammatory, and immunoregulatory/suppressive. 9, 11, 16 Although these categories have been investigated previously in isolation, we suggest that an integrative and simultaneous examination is likely to be more useful and meaningful. Here, we discuss mechanisms through which chronic stress is thought to dysregulate immune function through: 1) the suppression of protective immunity, 2) the induction/exacerbation of chronic inflammation, and 3) the enhancement of immunosuppressive mechanisms ( Fig. 1 ).
Chronic stress-induced suppression of protective immune responses
Protective immune responses include those that promote efficient healing of open as well as sterile wounds, eliminate infections and cancer, mediate cancer immunosurveillance, enable tumor immunotherapy, and drive vaccine effectiveness. 9, 11, 16 Effective immunoprotection is mediated by robust immunosurveillance, a rapid response to activation, clearance of the antigen/pathogen, and rapid and complete resolution of inflammation. 9, 11, 16 Immunoprotective responses are crucial during the inflammatory phase of wound healing, which is critical for subsequent proliferative and remodeling phases to be completed effectively. Wound healing is important for open wounds, sterile wounds, and collateral tissue damage caused by the activity of immune cells and cytokines. 9, 11, 16 Innate, adaptive, type 1, and type 2 immune responses all confer immunoprotection.
Protective immunity is critical for eliminating immunogenic cancers, such as squamous cell carcinoma (SCC) and basal cell carcinoma; virally associated cancers, such as HPV-associated cervical, anal, and oral cancers; and tumors that are made immunogenic through immunotherapy. It is noteworthy that, whether a tumor is immunogenic or not, immunoprotective responses are crucial for the health and survival of a patient with cancer, because they are essential for protecting the individual from wounds, opportunistic infections, and cancer treatment-induced tissue damage. Furthermore, immunoprotective responses are essential for the success of any cancer treatment, including tumor immunotherapy, which aims to render a tumor immunogenic and make it susceptible to elimination by immune cells. Thus, the suppression of protective immunity is 1 critical pathway through which chronic stress can exacerbate tumor emergence, progression, and metastasis.
Numerous studies have elucidated mechanisms and pathways through which chronic stress suppresses protective immunity. 9,11 Catecholamine 7 and glucocorticoid 26 hormones have been identified as the major physiologic mediators of chronic stress-induced suppression of protective immunity, although further research into other factors is necessary. One mechanism through which chronic stress suppresses immunoprotection is by decreasing/altering immune cell redistribution between different body compartments. 10 In human and animal studies, it has been demonstrated that chronic stress also suppresses different dimensions of protective immunity, including: cell-mediated immunity (CMI), antibody responses, immune cell proliferation, graft rejection, T-cell-driven and natural killer (NK)-driven antiviral responses, and macrophage-driven antimycobacterial activity. 22, [25] [26] [27] NK cell activity, CMI, and other types of immune responses are important for tumor surveillance and for inhibiting tumor progression, invasion, and metastasis. 6, [28] [29] [30] Chronic stress-induced suppression of multiple aspects of protective immunity mediates increased susceptibility to cancer. For example, in a naturalistic model of SCC in mice, the emergence and progression of precancerous and cancerous lesions was accelerated by chronic stress. Chronic stress suppressed gene expression of cutaneous-T-cell-attracting chemokine/C-C motif chemokine ligand 27 (CTACK/CCL27), which is critical for recruiting T cells to the site of immune activation. This was accompanied through the suppression of infiltration by protective cluster of differentiation 4 (CD4)positive and CD8-positive T cells and the inhibition of Th1 cytokines (IL-12 and interferon-γ [IFN-γ]), resulting in an overall suppression of immunoprotection. It is work noting that, in addition to suppressing protective immune responses, chronic stress enhanced immunosuppression by increasing regulatory/suppressor T cell (CD4-positive/CD25-positive) numbers in the tumor microenvironment and within the systemic circulation. 6 Similar to the effects of chronic stress, a high-anxious behavioral phenotype measured and identified at baseline (before naturalistic tumor induction) was associated with a higher tumor burden throughout the time course of tumor development. High-anxious mice exhibited higher corticosterone concentrations, indicating greater chronic stress. They also exhibited increased CCL22 expression and corresponding regulatory T-cell (Treg)
Cancer May 1, 2019 infiltration, indicating greater immunosuppression. This was accompanied by suppressed CTACK/CCL27, IL-12, and IFN-γ gene expression and CD4-positive and CD8-positive infiltration within and around tumors, indicating suppressed protective immunity, and by increased VEGF concentrations, indicating increased potential for tumor angiogenesis and metastasis. 31 Taken together, these results demonstrate that the tumor-exacerbating effects of high trait anxiety could be worsened by life stressors, cancer diagnosis, and treatment-related stressors, which, in turn, could contribute to increased tumor progression and/or metastasis. These results also highlight the importance of investigating the targeted use of chemotherapy-compatible anxiolytic treatments immediately after cancer diagnosis and during cancer treatment/ survivorship.
Studies in patients with different types of advanced-stage cancers have demonstrated that chronic stress can suppress cancer-relevant immune responses through catecholamine and glucocorticoid hormonemediated mechanisms. 4 Patients with metastatic breast cancer who had higher average diurnal cortisol concentrations and more depressive symptoms, indicating a higher level of chronic stress, had significantly suppressed CMI. 32 Depression also relates to suppressed NK cell cytotoxicity (NKCC) and T-cell cytokine production within the tumor microenvironment in patients with ovarian cancer; whereas social support, which is thought to be a chronic stress buffer, is associated with higher NKCC in the tumor microenvironment and circulation in these patients. 33, 34 In women with ovarian cancer, social support and vigor were associated with higher percentages of NK-T cells within the tumor and in peripheral blood, respectively, 35 whereas social isolation was associated with higher levels of tumor norepinephrine. 36 In patients with breast cancer who had early stage disease, lower anxiety in the weeks after surgery was associated with greater production of IL-2 after anti-CD3 (T-cell receptor) stimulation, whereas greater positive mood was associated with increased IL-12 and IFN-γ production. 37 Another study of patients with early stage breast cancer demonstrated that increased stress was associated with lower NKCC, lower NK cell response to stimulation by IFN-γ, and lower T-cell proliferation response to stimulation by lectins or anti-CD3. 38 A recent longitudinal analysis of the latter cohort revealed that decreases in stress and depression paralleled increases in NKCC over 18 months. 39 In sum, across observational studies in patients with different cancers at early and more advanced stages, chronic stress/distress states appear to be associated with dampened immunoprotective responses, whereas factors like social support, which are thought to buffer against the effects of chronic stress, are associated with more robust immunoprotective responses.
Chronic stress-induced exacerbation of chronic inflammation
Chronic stress may induce a sustained increase in circulating proinflammatory factors, such as IL-6, IL-1β, and C-reactive protein (CRP), and shift the cytokine balance from Th1 cytokines, which promote tumor-protective CMI, to Th2 cytokines, which promote antibodymediated immunity. [40] [41] [42] Although short-term elevations in IL-6 and IL-1β are crucial for launching and sustaining immunoprotective responses, chronic elevation of these factors leads to chronic inflammation, which is known to contribute to proinflammatory and autoimmune disorders and poorer cancer outcomes.
It is believed that chronic inflammation is a critical factor for tumor initiation, progression, and metastasis [43] [44] [45] through multiple pathways, including increased oxidative damage and oxidative stress, DNA mutations, release of factors like matrix metalloproteases (MMPs) that enable tumor invasion, and factors that induce angiogenesis and metastasis. Evidence for chronic inflammation-induced tumor formation comes from studies that demonstrate increased incidence of cancers at sites of chronic inflammation. For example, inflammatory bowel disease, Crohn's disease, and ulcerative colitis are associated with colorectal cancers; cystitis and bladder inflammation are associated with bladder cancer; gingivitis and lichen planus are associated with oral SCC; chronic pancreatitis is associated with pancreatic cancer; and skin inflammation is associated with melanoma. 43 In addition to exacerbating tumor progression and metastasis, chronic inflammation also contributes to cancer-related fatigue, depression, and sleep disturbance, all of which can negatively affect the patient's quality of life (QoL) and disease progression (for reviews see Bower and Lamkin and Irwin and colleagues [46] [47] [48] .
Over the past several years, studies have examined how multiple indicators of adversity (cancer-specific distress/anxiety, negative affect, depressive symptoms, social adversity) relate to inflammation (serum cytokines, leukocyte gene expression, and upstream processes, such as leukocyte nucleus nuclear factor κ-light chain activator of B cells [NF-κB] DNA binding) in patients with breast cancer. [49] [50] [51] [52] For instance, greater depressive symptoms relate to greater serum tumor necrosis factor α (TNF-α), IL-1β, and IL-6 levels in patients with breast cancer Cancer May 1, 2019 during the weeks after surgery. 51 In that cohort, greater postsurgical depressive symptoms also predicted shorter 11-year overall survival, 53 which is in line with prior reports on patients with breast cancer. 54, 55 Greater negative affect and less positive affect in postsurgical patients with breast cancer also were related to greater leukocyte gene expression for proinflammatory cytokines (eg, TNF-α, IL-1B, and IL-6 ), inflammatory chemokines and related receptors (CCL3, CCL3L1, CCL4L2, CCL7, CCL20, C-X-C motif chemokine 10 [CXCL10], CXCR6, and CXCR7), cooxygenase-2/prostaglandin-endoperoxide synthase 2 (COX2/PTGS2), and tissue remodeling and epithelial-mesenchymal transition (EMT)-related genes (eg, lamin A/C [LMNA], MMP-9). 56 Gene ontology analyses confirmed that genes upregulated with greater negative affect were disproportionately associated with proinflammatory and wound-healing activities. Thus, chronic stress and adversity are related to immune cell behavior in ways that can influence inflammatory signaling and possibly metastatic potential in women who are receiving treatment for breast cancer.
Similar associations have been identified in other cancers. For instance, greater depressive symptoms were associated with greater leukocyte proinflammatory (cytokine, chemokine, COX2/PTGS2) and prometastatic gene expression in patients with metastatic renal cell carcinoma (RCC), consistent with increased activity of NF-κB and signal transducer and activator of transcription 1 (STAT1) transcription factors and factors involved in myeloid cell activation and differentiation. 57 These results are remarkably similar to those noted above in patients with breast cancer. 48 In this study, patients who had RCC with greater depressive symptoms also had greater numbers of CD68-positive tumor-associated macrophages and greater proinflammatory (COX2/ PGE) and prometastatic (MMP2, MMP9) gene expression in tumor tissue. 57 Greater depressive symptoms and hypothalamic-pituitary-adrenal (HPA) axis dysregulation (flatter diurnal salivary cortisol slope) also predicted shorter survival time in this cohort. 57 In patients with ovarian cancer, adversity indicators (depression, low social support, social isolation) have been related to greater inflammatory gene expression in ovarian tissue, 58 greater levels of the tumor promoters VEGF and IL-6, increased macrophage expression for these tumor promoters, 59 and shorter survival. 60 In a recent study that provided an in vivo analysis of dynamic changes in tumor exosomes (intact cell-derived vesicles from tumor cells involved in intracellular signaling 61 ), before surgery, patients who had advanced ovarian cancer with low social support (vs high social support) exhibited the upregulation of 67 genes with mesenchymal characteristics and the downregulation of 63 endothelial-characteristic genes in circulating tumor cells, which could support enhanced EMT. 61 Secondary analyses implicated the upregulation of genes associated with heightened sympathetic nervous system (SNS) activity and NF-κB family transcription factors. 61 Thus, during the perisurgical period of ovarian cancer, as in the case of breast cancer 56 and RCC, 57 greater adversity is associated with greater inflammatory signaling and processes favoring metastasis and poorer clinical outcomes.
Chronic stress-induced enhancement of immunoregulatory/suppressive mechanisms
Recent studies indicate that chronic stress increases the numbers of Tregs 6 and regulatory B-cells (Bregs), myeloid-derived suppressor cells (MDSCs), and tumorassociated macrophages in the context of cancer. 30, 31, 62 It is known that Tregs are increased in the context of different types of cancer, 6, 30, 63 are recruited to the tumor microenvironment and suppress protective antitumor immune responses, and are associated with a poor prognosis and increased mortality. 64 Similarly, it has been demonstrated that Bregs suppress antitumor immune responses and are associated with a poor prognosis. 65, 66 MDSCs represent another cell type that suppresses antitumor immunity; it is also believed that they create conditions that promote tumor invasion and metastasis (eg, EMT) 67, 68 and indicate a poor prognosis. 69 However, it also has been demonstrated that lower stress levels are related to higher numbers of MDSCs, 70 thus suggesting a need for further research into the effects of chronic stress on MDSCs and on immune-regulatory/suppressive cell types in general.
Potentially Harnessing the Immunoenhancing Effects of Short-Term Stress in the Context of Cancer
In contrast to the effects of chronic stress, it has been demonstrated that short-term stress enhances protective immune responses, especially in compartments (eg, skin) to which some leukocytes traffic during stress. 9, 11, 26 Thus, short-term stress, when coupled with immune activation, enhances wound infiltration by leukocytes 71 as well as innate/primary 72, 73 and adaptive/secondary 26, 74, 75 immune responses. In contrast to these findings, several studies by Ben-Eliyahu et al have indicated that surgery stress, which can be considered to be a short-term stressor, results in suppressed immunity and increased Cancer May 1, 2019 tumor metastasis and that these effects can be reversed by prophylactic treatment with β-adrenergic antagonists and COX-2 inhibitors. 76, 77 These findings suggest that there are conditions under which short-term stress does not enhance antitumor immunity.
In addition to the above-mentioned preclinical studies, clinical studies also have demonstrated that patients who mount an a priori defined adaptive stress response during surgery have a significantly enhanced recovery compared with patients who fail to mount an adaptive stress response. 78 Furthermore, an elegant series of studies has demonstrated that the adjuvant effects of short-term psychological stress, or exercise stress, administered before vaccination, can enhance vaccineinduced immunity in humans. [79] [80] [81] These findings have led to the suggestion that the short-term stress response is Mother Nature's endogenous adjuvant that kicks into gear during times of stress, which often are accompanied by wounding and pathogen entry and require mounting an immune response to heal wounds and fight pathogens. 9, 11, 16 In the context of skin cancer, it has recently been demonstrated in a mouse model that short-term stress (2.5-hour restraint), administered 3 times a week for 3 weeks during a naturalistic ultraviolet light-induced tumor induction protocol, results in lower SCC tumor incidence and fewer tumors. 82 These effects are mediated by increased expression of CTACK/CCL27, RANTES (regulated on activation, normal T-cell expressed and secreted), IL-12, and IFN-γ gene expression and increased numbers of skin-infiltrating T cells. 82 Although findings that demonstrate short-term stress-induced enhancement of antitumor immunity need to be interpreted cautiously and replicated, they suggest that short-term stress could enhance antitumor immunity just as it enhances other aspects of innate and adaptive immunity. These findings also raise the intriguing possibility that the beneficial effects of exercise/physical activity in the context of cancer 83,84 may be mediated, at least in part, by the activation of short-term stress physiology and its adjuvant-like effects on antitumor immunity. We recognize that much work remains to be done: stress-induced enhancement of immune function may not be applicable to all types of cancer, and hypothesizing that short-term stress physiology could be harnessed to enhance antitumor immunity and cancer treatment, at first glance, may seem counterintuitive and controversial. At this point, we suggest that more preclinical and clinical studies should be conducted to safely test this hypothesis, elucidate potential mechanisms, and, if the results pan out, to design interventions that harness short-term stress physiology to enhance the effectiveness of cancer treatment.
SM AND THE IMMUNE PROCESSES IN PATIENTS WITH CANCER
Because modifying stress processes might facilitate psychological adaptation to cancer and better health outcomes, randomized controlled trials (RCTs) have tested interventions that can be considered SM at various points along the cancer continuum. 1, 85 Despite the impressive numbers of psychological interventions tested to date, few have experimentally demonstrated that SM can modulate psychological adaptation in patients who have cancer in parallel with: 1) changes in stress physiology (decreased or normalized SNS and HPA activity), 2) immune changes (decreased inflammation and improved CMI), and 3) long-term effects on QoL and disease course (recurrence, mortality). Such studies are rare, because they require recruiting patients into an RCT at a specific juncture in the cancer continuum (eg, during primary treatment or at the point of disease recurrence), inducing improvements in psychological distress and physiological stress responding (SNS and HPA markers) through SM, monitoring changes in immune parameters, and following cohorts for several years for clinical outcomes. First, we present evidence that various SM approaches are associated with changes in stress/adversity and with neuroendocrine and immune system variables over relatively short periods in patients with cancer and survivors; then, we highlight research demonstrating long-term clinical benefits that appear to be tied to immunologic changes ( Fig. 1 ).
SM Effects on Immune Parameters in Patients With Cancer
Many SM interventions that have been tested in patients with cancer work by changing bodily tension and physiologic activation through "physical" techniques, such as muscle relaxation training (RT), deep breathing, yoga and Tai-Chi, massage, acupuncture, and biofield therapies. Others work by increasing awareness and developing a nonjudgmental attitude toward stressful thoughts using mindfulness techniques. 86 Still other methods work by teaching skills for changing cognitive appraisals of stressful stimuli and coping with stressors through cognitive behavioral therapy (CBT) techniques, such as cognitive restructuring and coping effectiveness training, and building interpersonal/communications skills to better access and maintain coping resources, such as social support. 87, 88 Additional psychosocial/ behavioral interventions have exhibited efficacy in cancer populations but are not reviewed here, because we explicitly targeted stress-reduction approaches. These include supportive-expressive therapy 89 targeting existential issues; palliative care interventions targeting symptom management; 90 and physical exercise interventions targeting physical activity, strength, and fitness. 91 
Physical-based SM approaches
Meta-analyses have demonstrated that yoga has reliable effects on reducing distress, anxiety, and depression in patients with cancer. 92 Breast cancer survivors who were assigned to 12 weeks of yoga had decreased levels of proinflammatory serum cytokines in 2 trials, 93, 94 and Tai-Chi produced decreased leukocyte inflammatory gene expression in breast cancer survivors in 1 trial. 95 More passive physical SM approaches that involve external manipulation of skin, muscles, nerves, and energy fields by trained interventionists produced increased or stabilized NK cell counts or NKCC in patients with cancer. These approaches include massage (patients with breast cancer who are receiving radiation 96 ), acupuncture with warmed needles (moxibustion; patients with colorectal cancer who are receiving chemotherapy 97 ), and biofield therapy/healing touch (patients with cervical cancer who are receiving chemoradiation 98 ). All of these trials were based on small samples and short follow-up periods, and they lacked information on long-term clinical outcomes.
Mindfulness-Based Stress Reduction
Mindfulness-based stress reduction (MBSR) typically involves from 4 to 8 weeks of training in meditation techniques (awareness-raising and mindful movement), mindfulness and stress physiology, and a group support. MBSR reduces pain, anxiety, and negative mood among patients with breast cancer. 99 Two RCTs in breast cancer survivors demonstrated that those who were assigned to 6 weeks of MBSR had greater postintervention lymphocyte proliferative responses (LPRs) to mitogen stimulation and increases in the ratio of Th1:Th2 cytokines produced compared with controls. 100, 101 Among younger breast cancer survivors (aged ≤50 years), a 6-week (2 hours per week), group-based mindfulness intervention (vs wait-list controls) produced decreased depression and perceived stress along with changes in the expression of a 19-gene composite in leukocytes, reflecting reduced NF-κB activity and increased anti-inflammatory glucocorticoid receptor (GR) and IFN type-I gene expression. 102 Although these findings are encouraging, much of the work is limited by small sample sizes, short follow-up, and a lack of information on long-term clinical effects.
Cognitive-behavioral approaches
A CBT-based SM group intervention that included relaxation and stress reduction exercises, coping skills training, and health behavior change strategies provided over 12 months was tested in an RCT among women with stage II and III breast cancer who were recruited during the period after surgery. 87 Women in the intervention group (vs the standard-care group) had increases in cellular immunity (LPR) and reported decreased distress, more healthy eating habits (avoiding high-fat foods), and reduced smoking rates over the initial 4 months. 87 At 12-month follow-up, the intervention group had better health status based on staff ratings, and reductions in distress at 4 months predicted better health at 12 months. 103 Another CBT-based SM approach (CBSM) is a 10-week, group-based program that blends cognitive, behavioral, and interpersonal skills training through in-session didactic and role-playing activities, homework, and daily practice. 88 CBSM was shown in 2 RCTs of postsurgical patients who had stage 0 to III breast cancer, to improve cancer-specific distress, mood, social adversity, and QoL [104] [105] [106] ; decrease evening serum cortisol levels 107 ; and increase LPR and IL-2 and IFN-γ production. 108, 109 Demonstrating reductions in evening levels of cortisol is important, because flatter diurnal cortisol slopes (caused in part by higher evening levels) have been associated with decreased survival in patients with metastatic breast cancer, 110 nonsmall cell lung cancer, 111 and metastatic RCC. 57 Intervention effects on the production of Th1 cytokines (IL-2 and IFN-γ) may be important for supporting the cellular immune processes involved in tumor eradication. In that study, patients who were assigned to CBSM (vs controls) also had altered expression of 91 leukocyte genes at 6 to 12 month follow-up, including the down-regulation of 62 genes for proinflammatory cytokines (IL1B, IL6, TNF), inflammatory chemokines and their receptors, COX2/ PGS2, and mediators of tissue remodeling and EMT; and up-regulation of 29 genes related to CMI (antiviral) responses, including type I IFN response, type II IFN signaling, and IFN signal transduction. 56 Bioinformatic analyses of CBSM effects suggested decreased activity of NF-κB/Rel and the globin transcription factor (GATA) family and increased activity of IFN response factors that have been linked to stress and SNS signaling in prior work. 112 Patients who received CBSM also had increased expression of GR-related genes relative to controls and Cancer May 1, 2019 an over-representation of GR response elements in the promoters of CBSM-upregulated genes, 56 suggesting that CBSM may reverse stress-induced GR desensitization 11, 19 and subsequently downregulate inflammatory signaling. 113 
Do SM Interventions Affect Long-Term Clinical Outcomes in Patients With Cancer, and Are These Effects Associated With Immune System Changes?
The results from a meta-analysis of 15 randomized trials that met Cochrane criteria for methodological quality and involved nearly 3000 patients with cancer indicated that, although psychosocial interventions did not provide an overall survival benefit, interventions that were delivered early in the disease course (in 6 trials with 1448 patients who had nonmetastatic disease) were associated with a 41% reduced risk of cancer mortality. 114 We focus on 2 sets of studies among patients with nonmetastatic breast cancer patients who received postsurgical, CBT-based SM interventions to modulate psychological adaptation, cellular immune and/or inflammatory processes, and disease course.
Andersen et al tested the effects of a previously described postsurgical, group-based SM intervention 87 and reported a significant reduction in overall and breast cancer-specific mortality rates as well as a 45% reduced risk of cancer recurrence at a median of 11 years of follow-up. 115 In a subgroup of depressed women who were monitored over this follow-up period, those who received the intervention exhibited decreases in immunologic markers consistent with active infection or chronic inflammatory conditions (total white blood cells [WBCs] and neutrophils) compared with controls. 116 Women whose cancer recurred revealed greater serum cortisol levels and greater inflammation (greater total WBCs and neutrophils) 17 months before their recurrence. 117 Women who experienced a distal recurrence at this point had weaker cellular immune responses (LPR, NKCC) and greater elevations in WBCs compared with those who experienced a local recurrence. 117 Thus, a possible explanation for intervention effects on recurrence may be the normalization of stress-associated and treatmentassociated neuroendocrine and immunologic regulation during a critical period after treatment and preceding recurrence. The same team also followed women after the point of disease recurrence and observed a reduced risk of death over an 80-month follow-up among those who had been assigned to the intervention arm (vs the control arm) during primary treatment years ago. 118 During the 12 months after recurrence, the intervention group also exhibited improved psychological adaptation (decreased negative mood and increased social support) and greater LPR and NKCC. This set of studies suggests a that CBT-based SM intervention capable of improving psychological adaptation (decreased distress) may increase cellular immune function (LPR) early in treatment, prevent inflammatory changes during survivorship, and decrease the odds of mortality and recurrence. The receipt of this intervention during primary treatment also may promote persisting benefits in psychological adaptation, immune functioning, and clinical outcomes, even after disease recurs.
In another previously described RCT, [104] [105] [106] [107] [108] [109] women with stage 0 to III breast cancer who were assigned to a 10-week CBSM intervention (vs a psychoeducational control intervention) after surgery had lower odds of mortality and recurrence after 8 to 15 years of follow-up (median, 11 years) over and above the effects of age, time since surgery, stage, tumor receptor type, tumor size, and adjuvant therapy. 119 In analyses of patients who were matched for the same disease stage (stage II-III) as the patients enrolled in the trial by Andersen et al, 115 CBSM resulted in even larger reduction in the odds of breast cancer mortality and recurrence. 119 Among long-term survivors in that trial, those who had been assigned to CBSM exhibited less depressive symptoms and better general, emotional, and physical well being versus controls at a median follow-up of 11 years, suggesting that maintaining psychological adaptation over the course of survivorship may support better clinical outcomes. 120 Because research has implicated inflammation and leukocyte recruitment in breast cancer progression, 121, 122 next, the same investigators explored whether SM-related changes in leukocyte transcriptional activities during primary treatment could explain the effects of CBSM on increased the time to recurrence in this cohort. To examine whether the immunologic changes observed after CBSM over the initial 12 months of primary treatment predicted 11-year disease-free survival, the investigators used a 53-gene composite, including 19 proinflammatory transcripts and 34 transcripts (inversely scored) related to type I IFN responses and antibody synthesis, based on prior research on stress and adversity. 4, 5, 56, 62 Patients who were assigned to CBSM had decreased gene expression composite scores compared with controls, and a greater magnitude of decrease in the gene expression composite score over 12 months of primary treatment predicted greater 11-year disease-free survival. 123 It is plausible that other SM interventions with positive effects on breast Cancer May 1, 2019 cancer disease recurrence (eg, see Andersen et al 115 ) may operate by similar mechanisms. This also may have implications for SM in other cancers, because greater expression of this same combination of genes also predicted an increased risk of relapse and decreased leukemia-free survival in recipients of hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia. 124 Although they were conducted by independent laboratories, the 2 CBT-based SM trials reviewed here were comparable in terms of sample size, timing (postsurgical period before starting adjuvant therapy), intervention features (format, group; content, CBT-based SM; frequency, weekly for initial training), and follow-up intervals (psychological and immune measures over 12 months; disease outcomes over a median of 11 years). In each trial, distress and/or cortisol decreases were related either to increased frequency of relaxation practice 125 or to increased confidence in using SM skills. 126 The trials provide insight into the possible "active ingredients" of these interventions. Although the disease stage range of the samples did differ, when stage was matched between the 2 trials (ie, using patients only with stage II-III disease), very similar results emerged for intervention effects on survival and recurrence. Differences in the studies included a longer period of continuous intervention (12 months 115 vs 10 weeks 119 ) and an additional focus on heath behavior change in 1 trial. 115 These results suggest that it may be possible to achieve longterm health benefits in the briefer program with a sole focus on SM skills training. Taken together, CBT-based SM might improve long-term health outcomes in patients with breast cancer by modulating immune cell activities (eg, inflammation and antiviral immune signaling) that have the potential to communicate with cancer cells and stroma to promote progression and metastasis. [4] [5] [6] 122 
Emerging Trends in SM Research

Effects of brief SM on stress and immune activity
Because it has been demonstrated that combined approaches that include either RT, CBT, and health education (HE) 87 or RT and CBT 88 can improve psychological adaptation, physiologic stress responses, and health outcomes in patients with cancer who are undergoing primary treatment, it is important to understand whether specific elements of these combined approaches are effective. This is key, because interventions that require from 10 weeks to 12 months may not be feasible in the clinical oncology setting. One "dismantling" trial that compared the effects of 5-week RT versus 5-week CBT versus 5-week HE indicated that patients with breast cancer who were assigned to either RT or CBT exhibited improved psychological adaptation (mood, cancerspecific distress) versus those wo were assigned to HE. 127 Recent evidence demonstrates that women assigned to either RT or CBT have reduced inflammatory signaling (circulating s100A8/A9 levels and leukocyte nuclear NF-κB DNA binding) versus those assigned to HE. 52, 128 This cohort is now being followed for long-term clinical outcomes. Thus, postsurgical interventions as brief as 5 weeks, focused on either RT or CBT, can improve adaptation and reduce inflammatory signaling in ways possibly relevant for breast cancer disease progression.
Remotely delivered SM interventions
Attending face-to-face group meetings may present challenges to specific cancer populations as they navigate health care appointments while maintaining employment and child care responsibilities, in those who are hesitant to attend structured groups in institutional settings, or in patients who must be isolated for infection control after procedures such as chemotherapy and HSCT. Technological innovations now make it possible to offer interventions at home over a broadband platform. 129 In RCTs, online programs that allow patients with breast cancer to create personal blog sites improved mood. 130 Although these venues provide support resources, less is known about the value of remotely delivered, empirically validated SM interventions that affect stress and immune parameters (eg, CBSM), although RCTs are underway examining their impact in patients with breast cancer. 131 Pharmacologic approaches to modulating stress pathways One pharmacologic approach targets stress physiology pathways more explicitly by using agents that antagonize SNS signaling (eg, nonselective β-adrenergic blockade) and inflammation (eg, COX2 inhibitors) ( Fig. 1) , because the chronic use of β blockers and COX inhibitors is associated with a reduced risk of cancer metastasis in humans, 132 and blocking these pathways in mice decreases metastasis. 133, 134 The perioperative period involves the release of catecholamines and prostaglandins caused by psychological and surgical stress and tissue damage. 134 A double-blind, placebo-controlled trial in patients with breast cancer demonstrated that perisurgical administration (beginning 5 days presurgery and extending to 6 days postsurgery) of a combined propranolol and etodolac regimen was associated with decreased EMT signaling and the downregulation of Cancer May 1, 2019 leukocyte proinflammatory/prometastatic GATA and epidermal growth factor family transcriptional factors. This regimen also mitigated increases in serum IL-6 and CRP and declines in stimulated production of the Th1 cytokines IL-12 and IFN-γ. 135 The pattern of downregulated proinflammatory and prometastatic signaling and upregulated antiviral signaling is very similar to what has been observed in patients with breast cancer who receive CBT-based SM approaches, such as CBSM, after surgery. 56, 109, 123 It may be plausible to test whether an initial presurgical propranolol-etodolac cocktail like this, combined with brief CBT-based SM, in the postsurgical period provides an optimal SM adjunctive regimen to facilitate the success of cancer treatments.
Addressing understudied populations
Ethnic minority groups suffer disproportionate morbidity and mortality and compromised QoL from cancers. Although interventions like CBSM have been efficacious in reducing stress and adversity in different patient groups, including black breast cancer survivors 136 and Hispanic men with prostate cancer, 137 the effects of such interventions on immune activity and clinical outcomes are unknown. Another needed application of this work is in the context of opportunistic infections. For instance, patients who have been treated for cancer have 4 times the risk of influenza-related mortality. 138 Because chronic stress can dampen the immune response to the influenza vaccine in older populations, 139 an ongoing RCT is examining the effects of a remotely delivered CBSM intervention on stress and immunologic responses to the influenza vaccine in distressed older women who are receiving primary treatment for breast cancer. 131 With evidence that stress processes contribute to immunologic and tumor cell biology changes and poorer clinical outcomes in skin, 31 lung, 111 ovarian, 60,61 renal, 57 hepatocellular, 140 and hematologic cancers, 124, 141 it is imperative that trials evaluate the effects of SM interventions on stress, immunologic outcomes, and health outcomes in these and other cancers.
Practical and Clinical Considerations
With growing evidence that psychosocial interventions may influence psychological adaptation, stress-related biobehavioral processes, and clinical health outcomes in patients with cancer, contemporary questions move to when, where, and for whom these interventions might be used in clinical oncology settings. Regarding "when" in the postdiagnosis cancer continuum to intervene, most evidence on the effects of these interventions has been demonstrated in either postsurgical patients or cancer "survivors" who have completed primary treatment months prior. The potential impact of these interventions on psychological adaptation and QoL is demonstrable among patients in both the early and later stages of cancer, and this should be a primary goal. Although there is provocative evidence that these interventions can create changes in stress-related biobehavioral processes for periods up to 12 months in patients with early stage nonmetastatic disease, it remains to be determined whether they are able to modulate these biobehavioral processes in patients with advanced cancers.
In terms of clinical outcomes, 2 SM trials have demonstrated effects on long-term recurrence and survival 115, 119 in patients with early stage disease who received interventions in the postsurgical period. Given the established effects of surgery on stress-related biobehavioral processes, it is arguable that the perisurgical period may be an important point to explore in further intervention trials among patients with cancer. This could include recruiting patients just after a biopsy-confirmed diagnosis, randomizing them to study conditions either before surgery (a period of heightened anxiety and stress) or in the weeks after surgery, then examining relative changes in biobehavioral processes before and after surgery and again before and after adjuvant therapy. This might illuminate the optimal timing of "early" interventions. We know from prior work that psychosocial interventions initiated before surgery are associated with improved 10-year survival in patients who are treated for gastrointestinal cancer, 142 yet few trials have tested for the immunologic effects of presurgical SM in patients with cancer. It is noteworthy that 1 study demonstrated that a 2-session SM intervention (teaching breathing, relaxing imagery, and coping skills) offered to men before prostate cancer surgery was related to decreases in mood disturbance and increases in NKCC 1 week presurgery and up to 48 hours postsurgery. 143 In the future, the relative benefits of these early administrations could be compared with the benefits of delaying the intervention to the postadjuvant, early survivorship period or beyond. In each case, these cohorts of patients could be followed for longer term outcomes to determine the impact of early versus delayed intervention. One trial did observe that patients who received a postsurgical SM intervention had greater survival after they recurred. 118 Future work should test the effects of these interventions delivered in the period just after notification of recurrence-a very stressful point in time that may be more stressful than the initial diagnosis of primary disease.
Cancer May 1, 2019 Aside from questions of "when" to intervene, questions regarding "where" to intervene are concerned with the format for delivering the intervention. Extended interventions requiring weekly group attendance over several months may not be practical within the context of primary treatment, as noted above, and ongoing trials are testing briefer forms and remote delivery platforms (using tablets and broadband connection) to determine whether they produce effects comparable to those produced with their longer and in-person versions. More work also should be conducted testing the effects of "embedding" SM interventions into adjuvant therapy settings, such as the chemotherapy infusion suite, which could be delivered in-person, through DVD recordings, or through a remote connection. Given the long periods that patients must spend in receiving chemotherapy, there is an opportunity to test the efficacy of these interventions in large numbers of patients who are receiving specific regimens, with the potential of providing immediate clinical benefits, such as relaxation, a sense of control, and self-efficacy during treatment and lasting benefits between and beyond infusion visits. Another extension of this work would include testing the effects of SM interventions embedded in the neoadjuvant chemotherapy or HSCT settings, among others.
In terms of the "who" question, we need more information on which subgroups of patients are likely to benefit the most from SM interventions. Although there is evidence that patients with greater cancer-specific distress, 144 pessimism, 104 and other psychosocial adversity indicators 145 experience the greatest effects of these interventions on psychological adaptation, there is no evidence to date that these psychosocial characteristics can predict the effects of an intervention on biobehavioral and long-term clinical health outcomes. Beyond psychosocial characteristics, it is also important to explore biomedical (eg, tumor phenotype and immune system status) and sociodemographic factors that can be used to identify which patients are most likely to experience psychological, biobehavioral, and health benefits. It also would be fruitful to test which host factors predict differential effects of 1 SM approach over another (eg, relaxation vs CBT vs β-adrenergic blockade). This line of work could be facilitated by secondary analyses of prior trials, provided there is sufficient power to identify leads, which would then require confirmation in future trials with targeted sampling of subgroups and a priori hypotheses testing for the relative effectiveness of different approaches between these subgroups. Therefore, as this field evolves, it will be important to examine other issues, such as the cost effectiveness of SM per se as well as the relative cost effectiveness of interventions that vary in length and delivery format; and, as research informs us of the host factors that predict optimal intervention effects, we can make use of in-depth yet efficient psychosocial screening with patient-reported outcomes for depressive symptoms, cancer-specific distress, personality and coping style, and social/interpersonal factors that are most relevant. In the future, the notion of "targeted SM" for specific patients with cancer may become part of mainstream precision oncology care.
CONCLUSIONS
Chronic stress and adversity are associated with neuroendocrine alterations (SNS, HPA), which can up-regulate inflammation and down-regulate protective immunity. Immune cells that have undergone such changes may not control cancer cells effectively and may act as stromal cells, communicating with the tumor microenvironment and circulating cancer cells to promote tumor growth mechanisms, invasiveness, extravasation into the circulation, and metastasis. Many RCTs demonstrate that physical-based, mindfulness-based, and CBTbased SM interventions and pharmacologic blockade of stress-related pathways can affect immune parameters in patients with cancer and survivors. It is noteworthy that research has now linked SM-associated changes in immune parameters early in treatment with long-term health outcomes in the context of early stage breast cancer. Thus, in addition to reducing chronic stress and adversity, SM intervention also can alter immune cell activity in a manner that may mitigate the biologic impact of stress early in treatment, and potentially influence disease progression and clinical outcomes in patients with cancer ( Fig. 1) .
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